ASCO25: MSD’s ADC candidate achieves 56.3% ORR in lymphoma trial
Zilovertamab vedotin, an antibody drug conjugate (ADC) developed by Merck & Co (MSD) to treat diffuse large B-cell lymphoma (DLBCL),…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology and Medical Device Network. Robert holds a BSc in Neuroscience and holds interests in neurological devices, infectious diseases, and company investment such as initial public offerings (IPOs). Contact Rob
-
-
Scynexis resumes dosing in Phase III MARIO study after lengthy delay
Scynexis has resumed dosing of its vaginal yeast infection drug Brexafemme (ibrexafungerp) in a Phase III trial after a 19-month…
-
What’s been agreed at this year’s World Health Assembly?
With the 78th World Health Assembly ending today, all eyes have been on this year’s World Health Organization (WHO) member’s…
-
ASCO25: Roche’s Itovebi combo reduces risk of death in breast cancer by 33%
Roche’s blockbuster vision for phosphoinositide 3-kinase (PI3K inhibitor) Itovebi (inavolisib) has been dealt a boost after the drug demonstrated further…
-
Countries formally adopt WHO’s Pandemic Agreement for future pandemics
After years of debates between governments, member states of the World Health Organization (WHO) have formally adopted the world's first…
-
GSK to spend $2bn on Phase III liver disease drug acquisition
Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire…
-
New £1bn cancer research hub planned for South London
Plans have been unveiled for The London Cancer Hub, a state-of-the-art cancer research and laboratory hub to be located in…
-
Synthetic control arms: full impact yet to be realised
Amid the brighter spotlights being directed at data use in clinical trials, synthetic control arms represent a unique approach. Synthetic…
-
Scancell shares up 6% after NHS partnership for fast-track cancer vaccine trial
Patients with an advanced type of skin melanoma in England will be given expedited access to a new vaccine being…
-
Tempest hits funding block for Phase III liver cancer drug-in-waiting
Tempest Therapeutics is charting rocky waters as it looks to secure a partner to advance its liver cancer drug through…
